Read by QxMD icon Read

AMA_1 vaccine

Tebit Emmanuel Kwenti, Adzemye Linus Moye, Adzemye Basil Wiylanyuy, Longdoh Anna Njunda, Theresa Nkuo-Akenji
BACKGROUND: Studies to assess the immune responses against malaria in Cameroonian children are limited. The purpose of this study was to assess the immune responses against Plasmodium falciparum merozoite surface protein-1 (MSP-119 ) and apical membrane antigen-1 (AMA-1) in children residing in the different epidemiological strata of malaria in Cameroon. METHODS: In a cross-sectional survey performed between April and July 2015, 602 children between 2 and 15 years (mean ± SD = 5...
November 9, 2017: Malaria Journal
Chuen Yang Chua, Ping Chin Lee, Tiek Ying Lau
The apical membrane antigen-1 (AMA-1) of Plasmodium spp. is a merozoite surface antigen that is essential for the recognition and invasion of erythrocytes. Polymorphisms occurring in this surface antigen will cause major obstacles in developing effective malaria vaccines based on AMA-1. The objective of this study was to characterize ama1 gene in Plasmodium knowlesi isolates from Sabah. DNA was extracted from blood samples collected from Keningau, Kota Kinabalu and Kudat. The Pkama1 gene was amplified using nested PCR and subjected to bidirectional sequencing...
September 2017: Journal of Genetics
Gabriela Arévalo-Pinzón, Maritza Bermúdez, Diana Hernández, Hernando Curtidor, Manuel Alfonso Patarroyo
The malarial parasite's invasion is complex, active and coordinated, involving many low and high affinity interactions with receptors on target cell membrane. Proteomics analysis has described around 40 proteins in P. vivax which could be involved in reticulocyte invasion; few have been studied with the aim of elucidating how many of them establish specific interactions with their respective host cells. Given the importance of knowing which of the parasite's protein regions are functionally important for invasion, minimum regions mediating specific interaction between Plasmodium vivax apical membrane antigen 1 (PvAMA-1) and its host cell were here elucidated...
August 30, 2017: Scientific Reports
Amarin Rittipornlertrak, Boondarika Nambooppha, Pacharathon Simking, Veerasak Punyapornwithaya, Saruda Tiwananthagorn, Sathaporn Jittapalapong, Yang-Tsung Chung, Nattawooti Sthitmatee
Babesia bovis, a parasite infecting cattle and buffalo, continues to spread throughout the developing world. The babesial vaccine was developed to be a sustainable alternative treatment to control the parasite. However, genetic diversity is a major obstacle for designing and developing a safe and effective vaccine. The apical membrane antigen 1 (AMA-1) is considered to be a potential vaccine candidate antigen among immunogenic genes of B. bovis. To gain a more comprehensive understanding of B. bovis AMA-1 (BbAMA-1), three B...
August 12, 2017: Infection, Genetics and Evolution
Jack Bibby, Yauba Saidu, Ama Umesi, Ngozi Moneke-Anyanwoke, Adedapo O Bashorun, Mariama Badjie Hydara, Ikechukwu Adigweme, Jane U Adetifa, Michael Okoye, Elishia Roberts, Ralf Clemens, Ananda S Bandyopadhyay, Abdul K Muhammad, Sarah Mulwa, Michael Royals, Courtney Jarrahian, David Jeffries, Beate Kampmann, Ed Clarke
The immunogenicity of fractional (one-fifth, 0.1 mL) intradermal doses of the inactivated poliovirus vaccine (ID fIPV) is positively correlated with the size of the intradermal fluid bleb. Training of vaccinators for campaign and routine ID fIPV administration should focus on generating an 8- to 10-mm bleb with each injection. Clinical Trials Registration NCT01847872.
September 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Mariana Vilela Rocha, Kátia Sanches Françoso, Luciana Chagas Lima, Tarsila Mendes Camargo, Ricardo L D Machado, Fabio T M Costa, Laurent Rénia, Francois Nosten, Bruce Russell, Mauricio M Rodrigues, Irene S Soares
Plasmodium vivax is the most widely distributed malaria species and the most prevalent species of malaria in America and Asia. Vaccine development against P. vivax is considered a priority in the global program for the eradication of malaria. Earlier studies have characterized the Apical Membrane Antigen 1 (AMA-1) ectodomain and the C-terminal region (19kDa) of the Merozoite Surface Protein 1 (MSP-1) of P. vivax as immunodominant antigens. Based on this characterization, we designed a chimeric recombinant protein containing both merozoite immunodominant domains (PvAMA166 -MSP119 )...
April 25, 2017: Vaccine
Qingli Niu, Zhijie Liu, Jifei Yang, Guiquan Guan, Yuping Pan, Jianxun Luo, Hong Yin
Apical membrane antigen-1 (AMA-1) has been described as a potential vaccine candidate in apicomplexan parasites. Here we characterize the ama-1 gene. The full-length ama-1 gene of Babesia sp. BQ1 (Lintan) (BLTAMA-1) is 1785 bp, which contains an open reading frame (ORF) encoding a 65-kDa protein of 594 amino acid residues; by definition, the 5' UTR precedes the first methionine of the ORF. Phylogenetic analysis based on AMA-1 amino acid sequences clearly separated Piroplasmida from other Apicomplexa parasites...
April 2017: Parasitology
Abhik Saha, Sejal Chauhan, Tamishraha Bagchi
BACKGROUND: Recombinant proteins and vaccine candidates of Plasmodium vivax have met with limited success. One of the reasons could be their effect on monocytes which are important in malaria pathogenesis. Our aim was therefore to investigate the effect of selected recombinant malarial proteins on monocytes functions. METHODS: Phagocytosis rate and respiratory burst of healthy individuals' monocytes treated with antigens were examined. The homing capacity of monocytes was studied by examining the mRNA level of chemokine receptors from patients and healthy individuals...
August 2016: Transactions of the Royal Society of Tropical Medicine and Hygiene
Mahamadou A Thera, Drissa Coulibaly, Abdoulaye K Kone, Ando B Guindo, Karim Traore, Abdourhamane H Sall, Issa Diarra, Modibo Daou, Idrissa M Traore, Youssouf Tolo, Mady Sissoko, Amadou Niangaly, Charles Arama, Mounirou Baby, Bourema Kouriba, Mahamadou S Sissoko, Issaka Sagara, Ousmane B Toure, Amagana Dolo, Dapa A Diallo, Edmond Remarque, Roma Chilengi, Ramadhani Noor, Sanie Sesay, Alan Thomas, Clemens H Kocken, Bart W Faber, Egeruan Babatunde Imoukhuede, Odile Leroy, Ogobara K Doumbo
BACKGROUND: The safety and immunogenicity of PfAMA1, adjuvanted with Alhydrogel(®) was assessed in malaria-experienced Malian adults. The malaria vaccine, PfAMA1-FVO [25-545] is a recombinant protein Pichia pastoris-expressed AMA-1 from Plasmodium falciparum FVO clone adsorbed to Alhydrogel(®), the control vaccine was tetanus toxoid produced from formaldehyde detoxified and purified tetanus toxin. METHODS: A double blind randomized controlled phase 1 study enrolled and followed 40 healthy adults aged 18-55 years in Bandiagara, Mali, West Africa, a rural setting with intense seasonal transmission of P...
August 30, 2016: Malaria Journal
Chantal Ama Agbemabiese, Toyoko Nakagomi, Yen Hai Doan, Loan Phuong Do, Susan Damanka, George E Armah, Osamu Nakagomi
Understanding of the genetic diversity and evolution of Rotavirus A (RVA) strains, a common cause of severe diarrhoea in children, needs to be based on the analysis at the whole genome level in the vaccine era. This study sequenced the whole genomes of six representative G2P[4] strains detected in Ghana from 2008 to 2013, and analysed them phylogenetically with a global collection of G2P[4] strains and African non-G2P[4] DS-1-like strains. The genotype constellation of the study strains was G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2...
November 2016: Infection, Genetics and Evolution
Ed Clarke, Yauba Saidu, Jane U Adetifa, Ikechukwu Adigweme, Mariama Badjie Hydara, Adedapo O Bashorun, Ngozi Moneke-Anyanwoke, Ama Umesi, Elishia Roberts, Pa Modou Cham, Michael E Okoye, Kevin E Brown, Matthias Niedrig, Panchali Roy Chowdhury, Ralf Clemens, Ananda S Bandyopadhyay, Jenny Mueller, David J Jeffries, Beate Kampmann
BACKGROUND: The introduction of the inactivated poliovirus vaccine (IPV) represents a crucial step in the polio eradication endgame. This trial examined the safety and immunogenicity of IPV given alongside the measles-rubella and yellow fever vaccines at 9 months and when given as a full or fractional dose using needle and syringe or disposable-syringe jet injector. METHODS: We did a phase 4, randomised, non-inferiority trial at three periurban government clinics in west Gambia...
August 2016: Lancet Global Health
Ricardo A Chaurio, M Andreína Pacheco, Omar E Cornejo, Ester Durrego, Craig E Stanley, Andreína I Castillo, Sócrates Herrera, Ananias A Escalante
Transmission-blocking (TB) vaccines are considered an important tool for malaria control and elimination. Among all the antigens characterized as TB vaccines against Plasmodium vivax, the ookinete surface proteins Pvs28 and Pvs25 are leading candidates. These proteins likely originated by a gene duplication event that took place before the radiation of the known Plasmodium species to primates. We report an evolutionary genetic analysis of a worldwide sample of pvs28 and pvs25 alleles. Our results show that both genes display low levels of genetic polymorphism when compared to the merozoite surface antigens AMA-1 and MSP-1; however, both ookinete antigens can be as polymorphic as other merozoite antigens such as MSP-8 and MSP-10...
June 2016: PLoS Neglected Tropical Diseases
Alessandra Torina, Antonio Cordaro, Valeria Blanda, Rosalia D'Agostino, Salvatore Scimeca, Maria E Scariano, Guido Sireci, Rossella Lelli
Babesiosis due to Babesia bigemina is a relevant tick-borne disease, affecting cattle worldwide. Many surface proteins of the pathogen including the Apical Membrane Antigen 1 (AMA-1) - have been analysed for vaccine and diagnostic purposes. This study focused on B. bigemina AMA-1 and on its use for the assessment of diagnostic tests. After bioinformatic analyses, AMA-1 codifying region was amplified and cloned into an expression vector used to induce protein synthesis in Escherichia coli cells. AMA-1 was purified by affinity chromatography and used to set up the best condition for an ELISA protocol...
January 2016: Veterinaria Italiana
Rafiou Adamou, Francine Chénou, Ibrahim Sadissou, Paulin Sonon, Célia Dechavanne, Abdelkader Djilali-Saïah, Gilles Cottrell, Agnès Le Port, Achille Massougbodji, Edmond J Remarque, Adrian J F Luty, Ambaliou Sanni, André Garcia, Florence Migot-Nabias, Jacqueline Milet, David Courtin
Antibodies that impede the invasion of Plasmodium falciparum (P. falciparum) merozoites into erythrocytes play a critical role in anti-malarial immunity. The Growth Inhibition Assay (GIA) is an in vitro measure of the functional capacity of such antibodies to limit erythrocyte invasion and/or parasite growth. Up to now, it is unclear whether growth-inhibitory activity correlates with protection from clinical disease and there are inconsistent results from studies performed with GIA. Studies that have focused on the relationship between IgGs and their in vitro parasite Growth Inhibition Activity (GIAc) in infants aged less than two years old are rare...
July 2016: Acta Tropica
Yan Shen, Jun Wang, Yuxiao Huang, Jiao Liang, Xuewu Liu, Dudu Wu, He Jiang, Ya Zhao, Yinghui Li
Malaria is a severe, life-threatening infectious disease that endangers human health. However, there are no vaccines or immune strategy of vaccines succeeding in both erythrocytic and pre-erythrocytic stage. During the liver stage of the Plasmodium life cycle, sporozoites invade the host liver cells. The sporozoites, then, induce a cellular immune response via the major histocompatibility complex (MHC) molecules on their surfaces. The cytotoxic T lymphocytes (CTLs) then recognize the corresponding antigen-MHC complex on the surfaces of these infected liver cells and kill them...
May 2016: Parasitology Research
Maryam Salavatifar, Sedigheh Zakeri, Akram Abouie Mehrizi, Sedigheh Mirkhazemi, Navid Dinparast Djadid
BACKGROUND: Acquired antibody responses following natural infection provide valuable information for selection of candidate antigens for malaria vaccines. Apical membrane antigen-1 of Plasmodium vivax (PvAMA-1) has potential as a component of a subunit vaccine for vivax malaria. In addition, genetic diversity in this antigen is responsible for challenges in the development of an effective PvAMA-1 based vaccine. Therefore, the main aim of this study was to determine whether allelic polymorphisms in pvama-1 influence the recognition of naturally occurring antibodies...
December 2015: Archives of Iranian Medicine
Juan Camilo Sánchez-Arcila, Marcelle Marcolino de França, Virginia Araujo Pereira, Mariana Pinheiro Alves Vasconcelos, Antonio Têva, Daiana de Souza Perce-da-Silva, Joffre Rezende Neto, Cesarino Junior Lima Aprígio, Josue da Costa Lima-Junior, Mauricio Martins Rodrigues, Irene Silva Soares, Dalma Maria Banic, Joseli Oliveira-Ferreira
BACKGROUND: Polyparasitism is a common condition in humans but its impact on the host immune system and clinical diseases is still poorly understood. There are few studies of the prevalence and the effect of malaria-intestinal parasite co-infections in the immune response to malaria vaccine candidates. The present study determines whether the presence of malaria and intestinal parasites co-infection is associated with impaired IgG responses to Plasmodium vivax AMA-1 and MSP-119 in a rural population of the Brazilian Amazon...
2015: Malaria Journal
Maryam Salavatifar, Sedigheh Zakeri, Nasim Hayati Roodbari, Navid Dinparast Djadid
OBJECTIVE: The apical membrane antigen-1 (AMA-1) is considered as a promising candidate for development of a malaria vaccine against Plasmodium parasites. The correct conformation of this protein appears to be necessary for the stimulation of parasite-inhibitory responses, and these responses, in turn, seem to be antibody-mediated. Therefore, in the present investigation, we expressed the Plasmodium vivax AMA-1 (PvAMA-1) ectodomain in Escherichia coli (E. coli), purified it using standard procedures and characterized it to determine its biological activities for it to be used as a potential target for developing a protective and safe vivax malaria vaccine...
2015: Cell Journal
Mun Yik Fong, Shen Siang Wong, Jeremy Ryan De Silva, Yee Ling Lau
The simian malaria parasite Plasmodium knowlesi is now recognized as a species that can cause human malaria. The first report of large scale human knowlesi malaria was in 2004 in Malaysia Borneo. Since then, hundreds of human knowlesi malaria cases have been reported in Southeast Asia. The present study investigates the genetic polymorphism of P. knowlesi DI domain of the apical membrane antigen-1 (AMA-1), a protein considered as a promising vaccine candidate for malaria. The DI domain of AMA-1 gene of P. knowlesi clinical isolates from Peninsular Malaysia was amplified by PCR, cloned into Escherichia coli, then sequenced and analysed...
December 2015: Acta Tropica
M A Someabozorg, S Mirkazemi, A A Mehrizi, F Shokri, N D Djadid, S Zakeri
Naloxone (NLX) has ability to shift the immune response to a Th1 profile. Therefore, the adjuvant efficacy of NLX with recombinant P. vivax apical membrane antigen-1(rPvAMA-1) in BALB/c mice was evaluated. Mice were immunized subcutaneously with purified rPvAMA-1 formulated with NLX (doses of 5 mg/kg body weight) alone or in combination with IFA. A significant increase in anti-PvAMA-1 IgG antibody after the second boost (mean OD490 = 2.08 and 2.17, in groups received, rPvAMA-1/NLX and rPvAMA-1/-NLX/IFA, respectively) was detected...
August 1, 2015: Parasite Immunology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"